Business
MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market
BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics
About this update from Quantum Cyber N.v.
[{"type":"text","content":"BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, today announced that its common stock commenced trading on the Nasdaq Capital Market today under the ticker symbol MYNZ. The shares closed above the offering price at $9.99. On November 4, 2021, the Company priced its firm commitment underwritten public offering (the \"Offering\") of 2,000,000 common shares at a public offering price of $5.00 per share. The gross proceeds to the Company from the Offering were $10,000,000, before deducting underwriting discounts, commissions and other expenses. Boustead Securities, LLC acted as the sole underwriter for the firm commitment Offering. The securities described above are being sold by Mainz Biomed N.V. pursuant to a registration statement, as amended, filed by the Company with the Securities and Exchange Commission (the \"SEC\"), which was declared effective on November 4, 2021. The Offering has been made only by means of a prospectus. A copy of the final prospectus related to the Offering may be obtained, when available, from Boustead Securities, LLC, via email: [email protected] or by calling +1 (949) 502-4408 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition, a copy of the final prospectus relating to the Offering may be obtained via the SEC's website at www.sec.gov. About Mainz Biomed N.V. Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis. For more information pleas...